Gilead Sciences, Inc. (GILD)
| Market Cap | 142.65B |
| Revenue (ttm) | 28.75B |
| Net Income (ttm) | 480.00M |
| Shares Out | 1.25B |
| EPS (ttm) | 0.38 |
| PE Ratio | 302.92 |
| Forward PE | 14.50 |
| Dividend | $3.87 (3.36%) |
| Ex-Dividend Date | Mar 14, 2025 |
| Volume | 4,307,226 |
| Open | 117.05 |
| Previous Close | 115.99 |
| Day's Range | 114.33 - 117.24 |
| 52-Week Range | 62.07 - 117.39 |
| Beta | 0.24 |
| Analysts | Buy |
| Price Target | 102.96 (-10.12%) |
| Earnings Date | Apr 24, 2025 |
About GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.
Financial StatementsAnalyst Forecast
According to 27 analysts, the average rating for GILD stock is "Buy." The 12-month stock price forecast is $102.96, which is a decrease of -10.12% from the latest price.
News
Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025
With the broader market facing volatility, a clutch of experts are recommending investors to look beyond mega-cap stocks like Meta, Amazon, and Netflix for opportunities in stocks with strong earnings...
Gilead Sciences sets aside $200 million to resolve HIV drug probe
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into the drugmaker's promotional speakers program for HIV drugs.
Why Gilead Sciences Remains A Buy After A 40% Rally
Two weeks ago, Gilead Sciences released financial results for the fourth quarter of 2024, which exceeded even my most optimistic expectations. The strong performance of its HIV franchise was driven by...
MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gilead's Trodelvy® in Advanced Breast Cancer
LAUSANNE, Switzerland & BARCELONA, Spain--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards of care to...
European Medicines Agency Validates Gilead's Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company's Marketin...
Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the trea...
Gilead Sciences to Present at Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health Ca...
Calls of the Day: Gilead Sciences and Merck
The Investment Committee debate the Calls of the Day in two biotech names.
U.S. FDA Accepts Gilead's New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for ...
Josh Brown's best stocks
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to detail his favorite stocks in the market right now.
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention
Tuesday, Gilead Sciences Inc GILD reported fourth-quarter 2024 adjusted EPS of $1.90, beating the consensus of $1.70.
Gilead Sciences: Strong Q4 Results And Huge Progress In HIV
Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results, a robust HIV franchise, and an imminent lenacapavir commercialization by summer 2025. Lenacapavir PrEP regimen, with 100% effective...
Gilead Sciences, Inc. (GILD) Q4 2024 Earnings Call Transcript
Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Company Participants Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier -...
Gilead quarterly results beat estimates
Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% and acquisition-related costs fell.
Gilead Sciences Announces 2.6 Percent Increase in First Quarter 2025 Dividend
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Dividend--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared an increase of 2.6% in the company's quarterly...
Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024. “Gilead delivered another ex...
Gilead Sciences: Diversification Strategy Not Derisked Enough Yet
Gilead Sciences: Diversification Strategy Not Derisked Enough Yet
KBRA Assigns Preliminary Ratings to Gilead 2025-1 Aviation Limited
NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to the Series A Notes and Series B Notes issued by Gilead 2025-1 Aviation Limited and Gilead Aviation (Warehouse) LLC,...
Final Trade: UBER, MP, MGNI, GILD
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Gilead: Strong Sales Growth Remains With Veklury And Beyond
Company sees strong growth in VEKLURY sales, driven by increased Covid-19 hospitalizations, with Q3 2024 sales up 9% to $692 million. LIVDELZI shows promise for long-term growth, with FDA Accelerated ...
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
Medicaid funding, totaling approximately $900 billion per year and serving around 72 million participants, and the 340B program are key focus areas for potential healthcare reforms.
Cognizant and Gilead Expand Partnership to Drive Greater Value Through Advanced Technology Applications
Cognizant will provide AI-driven solutions to enhance customer service, employee engagement, and business value TEANECK, N.J. , Jan. 30, 2025 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) has announced an ...
Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 guidance will be released o...
Gilead Sciences, US government settle patent case over HIV prevention drugs
Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware federal court.